Literature DB >> 32518148

Novel approaches to quantify CNS involvement in children with Pompe disease.

Aditi Korlimarla1, Gail A Spiridigliozzi1, Kelly Crisp1, Mrudu Herbert1, Steven Chen1, Michael Malinzak1, Mihaela Stefanescu1, Stephanie L Austin1, Heidi Cope1, Kanecia Zimmerman1, Harrison Jones1, James M Provenzale1, Priya S Kishnani2.   

Abstract

OBJECTIVE: To characterize the extent of CNS involvement in children with Pompe disease using brain MRI and developmental assessments.
METHODS: The study included 14 children (ages 6-18 years) with infantile Pompe disease (IPD) (n = 12) or late-onset Pompe disease (LOPD) (n = 2) receiving enzyme replacement therapy. White matter (WM) hyperintense foci seen in the brain MRIs were systematically quantified using the Fazekas scale (FS) grading system with a novel approach: the individual FS scores from 10 anatomical areas were summed to yield a total FS score (range absent [0] to severe [30]) for each child. The FS scores were compared to developmental assessments of cognition and language obtained during the same time period.
RESULTS: Mild to severe WM hyperintense foci were seen in 10/12 children with IPD (median age 10.6 years) with total FS scores ranging from 2 to 23. Periventricular, subcortical, and deep WM were involved. WM hyperintense foci were seen throughout the path of the corticospinal tracts in the brain in children with IPD. Two children with IPD had no WM hyperintense foci. Children with IPD had relative weaknesses in processing speed, fluid reasoning, visual perception, and receptive vocabulary. The 2 children with LOPD had no WM hyperintense foci, and high scores on most developmental assessments.
CONCLUSION: This study systematically characterized WM hyperintense foci in children with IPD, which could serve as a benchmark for longitudinal follow-up of WM abnormalities in patients with Pompe disease and other known neurodegenerative disorders or leukodystrophies in children.
© 2020 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32518148      PMCID: PMC7455359          DOI: 10.1212/WNL.0000000000009979

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

1.  A Case of Normal Pressure Hydrocephalus in Adult-Onset Pompe Disease.

Authors:  Maria C D'Amico; Valeria Di Tommaso; Roberta Di Giacomo; Antonio Di Muzio; Marco Onofrj
Journal:  J Neuromuscul Dis       Date:  2015

2.  Aneurysms and vacuolar degeneration of cerebral arteries in late-onset acid maltase deficiency.

Authors:  H A Kretzschmar; H Wagner; G Hübner; A Danek; T N Witt; P Mehraein
Journal:  J Neurol Sci       Date:  1990-09       Impact factor: 3.181

3.  Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Shinn-Forng Peng; Wuh-Liang Hwu
Journal:  Pediatr Res       Date:  2006-07-20       Impact factor: 3.756

4.  Beery-Buktenica Developmental Test of Visual-Motor Integration performance in children with traumatic brain injury and attention-deficit/hyperactivity disorder.

Authors:  Griffin P Sutton; Kimberly A Barchard; Danielle T Bello; Nicholas S Thaler; Erik Ringdahl; Joan Mayfield; Daniel N Allen
Journal:  Psychol Assess       Date:  2011-09

5.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.

Authors:  P S Kishnani; D Corzo; M Nicolino; B Byrne; H Mandel; W L Hwu; N Leslie; J Levine; C Spencer; M McDonald; J Li; J Dumontier; M Halberthal; Y H Chien; R Hopkin; S Vijayaraghavan; D Gruskin; D Bartholomew; A van der Ploeg; J P Clancy; R Parini; G Morin; M Beck; G S De la Gastine; M Jokic; B Thurberg; S Richards; D Bali; M Davison; M A Worden; Y T Chen; J E Wraith
Journal:  Neurology       Date:  2006-12-06       Impact factor: 9.910

6.  Oropharyngeal dysphagia in infants and children with infantile Pompe disease.

Authors:  Harrison N Jones; Carolyn W Muller; Min Lin; Suhrad G Banugaria; Laura E Case; Jennifer S Li; Gwendolyn O'Grady; James H Heller; Priya S Kishnani
Journal:  Dysphagia       Date:  2009-09-10       Impact factor: 3.438

7.  Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings.

Authors:  Yao-Tun Teng; Wen-Jen Su; Jia-Wei Hou; Shiu-Feng Huang
Journal:  Chang Gung Med J       Date:  2004-05

8.  Adult-onset acid maltase deficiency in siblings.

Authors:  Y Miyamoto; Y Etoh; R Joh; K Noda; I Ohya; M Morimatsu
Journal:  Acta Pathol Jpn       Date:  1985-11

9.  The emerging phenotype of long-term survivors with infantile Pompe disease.

Authors:  Sean N Prater; Suhrad G Banugaria; Stephanie M DeArmey; Eleanor G Botha; Erin M Stege; Laura E Case; Harrison N Jones; Chanika Phornphutkul; Raymond Y Wang; Sarah P Young; Priya S Kishnani
Journal:  Genet Med       Date:  2012-04-26       Impact factor: 8.822

10.  Small-fiber neuropathy in pompe disease: first reported cases and prospective screening of a clinic cohort.

Authors:  Lisa D Hobson-Webb; Stephanie L Austin; Sneha Jain; Laura E Case; Karla Greene; Priya S Kishnani
Journal:  Am J Case Rep       Date:  2015-04-03
View more
  3 in total

1.  Older age is a protective factor for academic achievements irrespective of treatment modalities for posterior fossa brain tumours in children.

Authors:  Jarmila Kruseova; Anna Sarah Kovacova; Michal Zapotocky; David Sumerauer; Ivana Pernikova; Darja Starkova; Adela Misove; Andrea Zichova; Vaclav Capek; Thorsten Langer; Antoinette Am Zehnhoff-Dinnesen; Tomas Eckschlager; Martin Kyncl
Journal:  PLoS One       Date:  2020-12-16       Impact factor: 3.240

2.  Is the brain involved in patients with late-onset Pompe disease?

Authors:  Jan J A van den Dorpel; Willemijn M C van der Vlugt; Marjolein H G Dremmen; Ryan Muetzel; Esther van den Berg; Roos Hest; Joni de Kriek; Esther Brusse; Pieter A van Doorn; Ans T van der Ploeg; Johanna M P van den Hout; Nadine A M E van der Beek
Journal:  J Inherit Metab Dis       Date:  2022-01-25       Impact factor: 4.750

3.  Behavioral, social and school functioning in children with Pompe disease.

Authors:  Aditi Korlimarla; Gail A Spiridigliozzi; Mihaela Stefanescu; Stephanie L Austin; Priya S Kishnani
Journal:  Mol Genet Metab Rep       Date:  2020-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.